PLX (Biotechnology) Stock Valuation & Fair Value Significantly overvalued
PLX (Biotechnology) trades at a blended P/E of 29.0, about 27% above its historical normal valuation, with a forward growth estimate of -58.8% and a PEG of —. Analysts' one-year estimates have been hit 9% of the time.
Valuation flags
- Overvalued by 27%
- Negative growth forecast
Frequently asked questions
Is PLX overvalued?
At a blended P/E of 29.0 versus its historical normal P/E of 22.8, PLX trades about 27% above its typical valuation. tickerseer currently rates it significantly overvalued.
What is PLX's fair value and PEG?
PLX trades at a blended P/E of 29.0 against a historical normal P/E of 22.8, and a forward growth estimate of -58.8%.
Has tickerseer's rating of PLX changed?
tickerseer's rating has been significantly overvalued since 2026-08-07.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.